Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
The Prolactinoma Problem
NEJM 300:313-315, Reichlin,S., 1979
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978
Successful Use of Bromocriptine in the treatment of a Patient with Chronic Portasystemic Encephalopathy
NEJM 296:793, Morgan,M.Y.,et al, 1977